Neurocognitive Disorders Program
3550 Hosp South
Duke University Medical Center
Durham, NC 27710
DUMC-3018 Med Ctr
Durham, NC 27710
Email: murali DOT doraiswamy AT duke DOT edu
Translational Neuroscience Division, School of Medicine
DIBS Faculty, Member, DIBS Executive Board
A world leader in the fields of cognitive neuroscience and neuropsychiatry, Murali directs a clinical trials unit focused on understanding the ageing brain, and on developing personal diagnostics and therapeutics for cognitive enhancement and mental well-being. His unit has been involved in the development of many of the leading products used today to treat neurological and psychiatric conditions such as Alzheimer's disease.
A native of Chennai, India, Murali obtained his medical degree from the University of Madras India and completed his internship and residency at Duke Medicine. He is currently the Director of the Neurocognitive Disorders Program and a Professor in the Translational Neuroscience division in the Department of Psychiatry. He is also a member of The Duke Center for Personalized Medicine.
Murali is a Fellow of the Royal College of Physicians (London), a Fellow of the American Neurological Association and a member of the World Economic Forum's Global Agenda Council on Neuroscience and Behavior. He also serves as an adviser to leading government agencies, biotech and digital health companies, and patient advocacy groups.
Murali is a brain health adviser for Men's Health magazine and serves on the healthcare panel of experts for the Wall Street Journal. He is coauthor of a popular book, The Alzheimer's Action Plan.
Medical School, University of Madras, India Internship and Residency, Duke University Med Center, USA
Layous K, Chancellor J, Lyubomirsky S, Wang L, Doraiswamy PM. Delivering happiness: translating positive psychology intervention research for treating depressive disorders. J Altern Complement Med. 2011.
Billeke P, Boardman S, Doraiswamy PM. Social cognition in major depression. Translational Neuroscience, 2014.
Doraiswamy PM, Sperling R, Johnson K, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular Psychiatry, 2014.
Copyright 2008-2014 DIBS and Duke University. All rights reserved.